Series A Investment Opportunity in Next-Generation Nucleic Acid Medicines

Eyam Health invites Japanese investors to participate in our $25M Series A as we advance a differentiated nucleic acid medicines platform with global commercial potential. Our Gemini platform is a carrier-optional self-amplifying plasmid that enables six-plus months of therapeutic protein expression from a single injection, supported by our Jennerator AI engine for nucleic acid sequence optimization. The foundational vector is described in Nature Communications, and the platform has been validated through Gates Foundation-funded programs and existing pharma partnerships across infectious disease, chronic conditions, and oncology.

Japan holds a strategically significant position in this space: regulators have already approved a self-amplifying RNA platform, establishing a meaningful precedent and a clearer clinical pathway for next-generation nucleic acid vectors such as Gemini. This regulatory familiarity makes Japan an attractive jurisdiction for development and partnership, and positions Japanese investors as early stakeholders in a platform poised to benefit from that momentum.

We welcome co-investment discussions with Japanese pharma, biotech, and life sciences investors seeking exposure to the next wave of nucleic acid medicines.